Drug Profile
Research programme: immunological disorders therapy - Five Prime Therapeutics
Alternative Names: FPA-031Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics
- Developer Centocor; Five Prime Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders; Inflammation; Osteoarthritis; Pulmonary fibrosis
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA